SMC accepts respiratory therapies

摘要

New treatments for asthma and chronic obstructive pulmonary disease (COPD) have been approved for use in NHS Scotland.In the latest set of appraisals by the Scottish Medicines Consortium,omalizumab (Xolair) has been accepted as an add-on asthma control therapy in patients aged 12 years and over with severe persistent allergic asthma.Formoterol (Atimos Modulite) inhaler has been accepted for the relief of broncho-obstructive symptoms in patients with COPD.